Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Tocilizumab

Anaphylaxis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Miyamae T, et al. LONG-TERM PROGNOSTIC FOLLOW-UP OF PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AFTER THE CLINICAL TRIAL OF TOCILIZUMAB AS A FIRST-LINE BIOLOGIC TREATMENT. Annals of the Rheumatic Diseases 82 (Suppl. 1): 671-672 abstr. POS0760, 2023. Available from: URL: http://doi.org/10.1136/annrheumdis-2023-eular.1034 [abstract] Miyamae T, et al. LONG-TERM PROGNOSTIC FOLLOW-UP OF PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AFTER THE CLINICAL TRIAL OF TOCILIZUMAB AS A FIRST-LINE BIOLOGIC TREATMENT. Annals of the Rheumatic Diseases 82 (Suppl. 1): 671-672 abstr. POS0760, 2023. Available from: URL: http://​doi.​org/​10.​1136/​annrheumdis-2023-eular.​1034 [abstract]
Metadaten
Titel
Tocilizumab
Anaphylaxis: case report
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48177-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Covid-19-vaccine

Case report

Lisinopril

Case report

Quinidine